UNDBIO

Vitrian has been engaged to manage the pursuit, design, entitlement, construction and economic incentive negotiation for UNDBIO,  a South Korean synthetic biology company initially focused on insulin biosimilars. UNDBIO is in the process of ramping up US-based production ahead of future clinical trials. In addition to traditional real estate responsibilities, Vitrian is also liaising on behalf of the company with local and state stakeholders including governmental and educational organizations.